Seeding trials: Just say "no"

Annals of Internal Medicine

Volumn 149, Issue 4, 2008, Pages 279-280

  Sox, Harold C ^a   Rennie, Drummond ^b  

^a AMERICAN COLLEGE OF PHYSICIANS   (United States)

^b NONE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

NAPROXEN; ROFECOXIB;

CLINICAL PRACTICE; CLINICAL TRIAL; DRUG INDUSTRY; DRUG MARKETING; EDITORIAL; ETHICS; FOLLOW UP; HEALTH CARE ORGANIZATION; LEGAL ASPECT; MEDICAL PRACTICE; PHYSICIAN ATTITUDE; POSTMARKETING SURVEILLANCE; PRACTICE GUIDELINE; PRESCRIPTION; PRIORITY JOURNAL; CONFLICT OF INTEREST; MARKETING; NOTE; RECUMBENCY; STANDARD;

CLINICAL TRIALS AS TOPIC; CONFLICT OF INTEREST; DECEPTION; DRUG INDUSTRY; MARKETING;

EID: 49849085406     PISSN: 00034819     EISSN: None     Source Type: Journal    
DOI: 10.7326/0003-4819-149-4-200808190-00012     Document Type: Editorial

References (10)

1. Psaty BM, Rennie D. Clinical trial investigators and their prescribing patterns: another dimension to the relationship between physician investigators and the pharmaceutical industry [Editorial]. JAMA. 2006;295:2787-90. [PMID: 16788134]
2. Andersen M, Kragstrup J, Søndergaard J. How conducting a clinical trial affects physicians' guideline adherence and drug preferences. JAMA. 2006;295: 2759-64. [PMID: 16788131]
3. Studdert DM, Mello MM, Brennan TA. Financial conflicts of interest in physicians' relationships with the pharmaceutical industry - self-regulation in the shadow of federal prosecution. N Engl J Med. 2004;351:1891-900. [PMID: 15509824]
4. Brennan TA, Rothman DJ, Blank L, Blumenthal D, Chimonas SC, Cohen JJ, et al. Health industry practices that create conflicts of interest: a policy proposal for academic medical centers. JAMA. 2006;295:429-33. [PMID: 16434633]
5. Department of Health and Human Services; Office of the Inspector General. OIG compliance program guidance for pharmaceutical manufacturers. Fed Regist. 2003;68:23731-43.
6. Lisse JR, Perlman M, Johansson G, Shoemaker JR, Schechtman J, Skalky CS, et al. ADVANTAGE Study Group. Gastrointestinal tolerability and effectiveness of rofecoxib versus naproxen in the treatment of osteoarthritis: a randomized, controlled trial. Ann Intern Med. 2003;139:539-46. [PMID: 14530224]
7. Egilman DS, Presler AH. Report of specific cardiovascular outcomes of the ADVANTAGE trial [Letter]. Ann Intern Med. 2006;144:781. [PMID: 16702599]
8. Hill KP, Ross JS, Egilman DS, Krumholz HM. The ADVANTAGE seeding trial: a review of internal documents. Ann Intern Med. 2008;149:251-8.
9. Kessler DA, Rose JL, Temple RJ, Schapiro R, Griffin JP. Therapeutic-class wars - drug promotion in a competitive marketplace. N Engl J Med. 1994;331: 1350-3. [PMID: 7935706]
10. Davidoff F, DeAngelis CD, Drazen JM, Hoey J, Højgaard L, Horton R, et al. Sponsorship, authorship, and accountability [Editorial]. Ann Intern Med. 2001;135:463-6. [PMID: 11560460]